While this does not affect Canada directly, it is a major step forward for the international community and acknowledges what Canada is already doing in...
The call for applications for the CHS’ research programs for the 2026-2027 grant period is ongoing. The deadline to submit applications for all the programs...
The CHS is very proud to present its latest publication, the first component of its brand-new Novel Therapies Education Program. CLICK HERE to access the online booklet.
MONTRÉAL, March 31, 2025 – Health Canada has granted marketing approval to Altuviiio (efanesoctocog alfa) for the treatment of hemophilia A in children, adolescents and...
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...